Monopar Therapeutics (MNPR) Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MNPR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Monopar Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.15 |
| 52 Week High | US$54.30 |
| 52 Week Low | US$2.29 |
| Beta | 1.07 |
| 1 Month Change | -16.07% |
| 3 Month Change | 6.35% |
| 1 Year Change | 1,328.87% |
| 3 Year Change | 279.47% |
| 5 Year Change | 30.34% |
| Change since IPO | -74.23% |
Recent News & Updates
Recent updates
Monopar Therapeutics: Strong Data, But There Are Risks
Mar 04We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Aug 13
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?
Feb 27Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?
Mar 02We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Nov 16Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive
Oct 05We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate
Jul 30Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Mar 28We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely
Jul 15Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
Mar 26Shareholder Returns
| MNPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.3% | -0.4% | 0.5% |
| 1Y | 1,328.9% | -9.9% | 15.7% |
Return vs Industry: MNPR exceeded the US Biotechs industry which returned -9.9% over the past year.
Return vs Market: MNPR exceeded the US Market which returned 15.7% over the past year.
Price Volatility
| MNPR volatility | |
|---|---|
| MNPR Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MNPR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MNPR's weekly volatility has decreased from 88% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 15 | Chandler Robinson | www.monopartx.com |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Monopar Therapeutics Inc. Fundamentals Summary
| MNPR fundamental statistics | |
|---|---|
| Market cap | US$210.70m |
| Earnings (TTM) | -US$17.31m |
| Revenue (TTM) | n/a |
Is MNPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNPR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.31m |
| Earnings | -US$17.31m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MNPR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/01 15:00 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Monopar Therapeutics Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |